Huang Kang, Lu Shi-Juan, Zhong Jiang-Hua, Xiang Qun, Wang Liu, Wu Miao
Department of Cardiology, Haikou People's Hospital, Haikou 570208, China.
Department of Cardiology, Haikou People's Hospital, Haikou 570208, China.
Asian Pac J Trop Med. 2014 Feb;7(2):144-8. doi: 10.1016/S1995-7645(14)60011-0.
To investigate the protective effect of different cyclosporin A (CsA) doses on myocardial ischemia/reperfusion injury in rat models.
A rat model of myocardial ischemia/reperfusion injury was established in vivo and the rats were randomly divided into four groups: placebo (PBS; T1), low-dose (CsA dose: 1.0 mg/kg; T2), medium-dose (CsA dose: 2.5 mg/kg; T3), and high-dose (CsA dose: 5.0 mg/kg; T4) groups. Heart function indexes were monitored at different time points, the extent of myocardial infarction was assessed by Evans Blue-TTC staining, and creatine kinase MB mass and cardiac troponin I values were measured by biochemical assays.
Compared with the T1 and T2 groups, both the creatine kinase MB mass and cardiac troponin I were significantly lower in the T3 and T4 groups (P<0.05). The mean arterial pressure (MAP) and left ventricular systolic pressure (LVSP) decreased sequentially in each group, with the extending reperfusion time. Significant decreases in LVSP and MAP were observed in the T3 and T4 groups as compared to the T1 and T2 group (P<0.05), and the T2 group showed a significantly lower LVSP and MAP decline than the T1 group (P<0.05). Compared with the T1 group, the rats from the T2, T3, and T4 groups suffered from a significantly lower extent of myocardial infarction (P<0.05). Also, the animals in the T3 and T4 groups had a significantly smaller extent of myocardial infarction than those in the T2 group (P<0.05).
Various CsA doses exert different degrees of protection against ischemia/reperfusion injury, and this protective effect peaks at approximately 2.5 mg/kg in rat models.
探讨不同剂量环孢素A(CsA)对大鼠心肌缺血/再灌注损伤的保护作用。
在体内建立大鼠心肌缺血/再灌注损伤模型,将大鼠随机分为四组:安慰剂组(PBS;T1)、低剂量组(CsA剂量:1.0 mg/kg;T2)、中剂量组(CsA剂量:2.5 mg/kg;T3)和高剂量组(CsA剂量:5.0 mg/kg;T4)。在不同时间点监测心功能指标,通过伊文思蓝-氯化三苯基四氮唑(Evans Blue-TTC)染色评估心肌梗死范围,采用生化分析法测定肌酸激酶同工酶MB质量和心肌肌钙蛋白I值。
与T1组和T2组相比,T3组和T4组的肌酸激酶同工酶MB质量和心肌肌钙蛋白I均显著降低(P<0.05)。随着再灌注时间延长,各组平均动脉压(MAP)和左心室收缩压(LVSP)依次下降。与T1组和T2组相比,T3组和T4组的LVSP和MAP显著降低(P<0.05),且T2组的LVSP和MAP下降幅度显著低于T1组(P<0.05)。与T1组相比,T2组、T3组和T4组大鼠的心肌梗死范围显著降低(P<0.05)。此外,T3组和T4组动物的心肌梗死范围显著小于T2组(P<0.05)。
不同剂量的CsA对缺血/再灌注损伤具有不同程度的保护作用,在大鼠模型中,这种保护作用在约2.5 mg/kg时达到峰值。